VistaGen Therapeutics Inc. (VTGN)
$0.24
$0.00
(-1.38%)
As on 04-Sep-2026 16:22EDT
Market cap
$11 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$0.6
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
44,376,911
10 Years Aggregate
CFO
$-163.35 Mln
EBITDA
$-222.37 Mln
Net Profit
$-258.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
VistaGen Therapeutics (VTGN)
| -63.3 | -0.9 | -56.7 | -93.4 | -65.5 | -69.7 | -45.7 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
VistaGen Therapeutics (VTGN)
| -77.6 | -42.3 | 66.3 | -94.9 | 0.5 | 181.3 | -54.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
VistaGen Therapeutics (VTGN)
|
0.2 | 10.8 | 2.5 | -67.6 | -2,720.3 | -179.4 | -- | 0.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout VistaGen Therapeutics (VTGN)
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an... investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Read more
-
CEO & Director
Mr. Shawn K. Singh J.D.
-
CEO & Director
Mr. Shawn K. Singh J.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for VistaGen Therapeutics (VTGN)
What is the current share price of VistaGen Therapeutics Inc (VTGN) Today?
The share price of VistaGen Therapeutics Inc (VTGN) is $0.24 (NASDAQ) as of 04-Sep-2026 16:22 EDT. VistaGen Therapeutics Inc (VTGN) has given a return of -65.51% in the last 3 years.
What is the current PB & PE ratio of VistaGen Therapeutics Inc (VTGN)?
Since, TTM earnings of VistaGen Therapeutics Inc (VTGN) is negative, P/E ratio is not available.
The P/B ratio of VistaGen Therapeutics Inc (VTGN) is 0.45 times as on 04-Sep-2026, a 91 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-0.32 |
0.64 |
2025 |
-1.49 |
1.09 |
2024 |
-4.86 |
1.25 |
2023 |
-0.02 |
0.07 |
2022 |
-0.18 |
0.13 |
What is the 52 Week High and Low of VistaGen Therapeutics Inc (VTGN)?
The 52-week high and low of VistaGen Therapeutics Inc (VTGN) are Rs 5.14 and Rs 0.20 as of 06-Sep-2026.
What is the market cap of VistaGen Therapeutics Inc (VTGN)?
VistaGen Therapeutics Inc (VTGN) has a market capitalisation of $ 11 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in VistaGen Therapeutics Inc (VTGN)?
Before investing in VistaGen Therapeutics Inc (VTGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.